跳轉至內容
Merck
  • Intermediate syndrome after malathion ingestion despite continuous infusion of pralidoxime.

Intermediate syndrome after malathion ingestion despite continuous infusion of pralidoxime.

Journal of toxicology. Clinical toxicology (2000-03-04)
D L Sudakin, M E Mullins, B Z Horowitz, V Abshier, L Letzig
摘要

A 33-year-old female ingested an unknown quantity of malathion in a suicide attempt. Cholinergic signs consistent with severe organ, phosphate intoxication developed and were treated within 6 hours of ingestion. Intravenous atropine and a continuous infusion of pralidoxime (400 mg/h) were administered. Prolonged depression of plasma and red blood cell cholinesterases were documented. Despite an initial clinical improvement and the presence of plasma pralidoxime concentrations exceeding 4 microg/mL, the patient developed profound motor paralysis consistent with the diagnosis of Intermediate Syndrome. In addition to the dose and frequency of pralidoxime administration, other factors including persistence of organophosphate in the body, the chemical structure of the ingested organophosphate, and the time elapsed between ingestion and treatment may limit the effectiveness of pralidoxime as an antidote in organophosphate ingestions. This case study suggests that these factors should be taken into account in assessing the risk of Intermediate Syndrome after intentional organophosphate ingestions.

材料
產品編號
品牌
產品描述

Supelco
马拉硫磷, PESTANAL®, analytical standard
Supelco
马拉硫磷 溶液, 100 μg/mL in cyclohexane, PESTANAL®, analytical standard
USP
马拉硫磷, United States Pharmacopeia (USP) Reference Standard
马拉硫磷, European Pharmacopoeia (EP) Reference Standard
Supelco
马拉硫磷, certified reference material, TraceCERT®